EMA Committee Recommends Six New Medicines, Including Oral GLP-1 for Weight Management

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for six new medicines. Notably, this includes Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. This recommendation could significantly impact the metabolic disease landscape, which is currently dominated by injectable treatments. Other recommended medicines address oncology, rare diseases, and ophthalmology, expanding treatment options across several medical fields.